125 related articles for article (PubMed ID: 3865500)
21. Large variations of plasma levels during maintenance treatment with depot neuroleptics.
Tuninger E; Levander S
Br J Psychiatry; 1996 Nov; 169(5):618-21. PubMed ID: 8932892
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of schizophrenics with perphenazine enanthate].
Madsen A; Sorensen J
Nord Psykiatr Tidsskr; 1971; 25(5):475-8. PubMed ID: 5144306
[No Abstract] [Full Text] [Related]
23. [A comparative study of the longacting neuroleptics perphenazin-enanthate and fluspirilene (author's transl)].
Tegeler J; Floru L
Pharmakopsychiatr Neuropsychopharmakol; 1979 Sep; 12(5):357-65. PubMed ID: 504342
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice.
Hansen LB; Larsen NE
Psychopharmacology (Berl); 1985; 87(1):16-9. PubMed ID: 3933033
[TBL] [Abstract][Full Text] [Related]
25. Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.
Viala A; Hou N; Ba B; Durand A; Dufour H; D'Agostino N; Berda C; Jørgensen A
Psychopharmacology (Berl); 1984; 83(2):147-50. PubMed ID: 6146995
[TBL] [Abstract][Full Text] [Related]
26. Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone.
Hendouei N; Farnia S; Mohseni F; Salehi A; Bagheri M; Shadfar F; Barzegar F; Hoseini SD; Charati JY; Shaki F
Biomed Pharmacother; 2018 Jul; 103():965-972. PubMed ID: 29710513
[TBL] [Abstract][Full Text] [Related]
27. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
Mazure CM; Nelson JC; Jatlow PI; Kincare P; Bowers MB
J Clin Psychiatry; 1990 Aug; 51(8):330-4. PubMed ID: 2199431
[TBL] [Abstract][Full Text] [Related]
28. Increase in weight after treatment with depot neuroleptics.
Korsgaard S; Skausig OB
Acta Psychiatr Scand; 1979 Feb; 59(2):139-44. PubMed ID: 420033
[TBL] [Abstract][Full Text] [Related]
29. Clinical pharmacokinetics of the depot antipsychotics.
Jann MW; Ereshefsky L; Saklad SR
Clin Pharmacokinet; 1985; 10(4):315-33. PubMed ID: 2864156
[TBL] [Abstract][Full Text] [Related]
30. Depot fluphenazine decanoate and enanthate for schizophrenia.
David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J
Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872
[TBL] [Abstract][Full Text] [Related]
31. Extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting-test study in 22 acutely ill schizophrenic patients.
Gerken A; Wetzel H; Benkert O
Pharmacopsychiatry; 1991 Jul; 24(4):132-7. PubMed ID: 1754609
[TBL] [Abstract][Full Text] [Related]
32. [Perphenazine enanthate. Results of a 1-year open multicenter study].
Baruch P; Brion S; Broussolle P; Gayral LF; Ropert R; Volmat R; Porot M
Encephale; 1989; 15(5):449-55. PubMed ID: 2686965
[TBL] [Abstract][Full Text] [Related]
33. Low serum neuroleptic levels predict relapse in schizophrenic patients.
Brown WA; Laughren T; Chisholm E; Williams BW
Arch Gen Psychiatry; 1982 Sep; 39(9):998-1000. PubMed ID: 6126172
[TBL] [Abstract][Full Text] [Related]
34. [Clinical study on five depot neuroleptics. Comparison of effective profiles of fluphenazinedecanoate, fluspirilene, penfluridol, perphenazine-enanthate and pipothiazinepalmitate].
Angst J; Woggon B
Arzneimittelforschung; 1975 Feb; 25(2):267-70. PubMed ID: 1091272
[TBL] [Abstract][Full Text] [Related]
35. Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
Bowers MB; Mazure CM; Nelson JC; Jatlow PI
Biol Psychiatry; 1992 Dec; 32(12):1102-7. PubMed ID: 1477190
[TBL] [Abstract][Full Text] [Related]
36. Comparison of serum levels after intramuscular injections of 2% and 10% cis(Z)-flupentixol decanoate in Viscoleo to schizophrenic patients.
Stauning JA; Kirk L; Jøorgensen A
Psychopharmacology (Berl); 1979 Sep; 65(1):69-72. PubMed ID: 116292
[TBL] [Abstract][Full Text] [Related]
37. A CONTROLLED STUDY OF FLUPHENAZINE ENANTHATE IN CHRONIC SCHIZOPHRENIC PATIENTS.
RAVARIS CL; WEAVER LA; BROOKS GW
Dis Nerv Syst; 1965 Jan; 26():33-9. PubMed ID: 14248511
[No Abstract] [Full Text] [Related]
38. Platelet monoamine oxidase activity in neuroleptic-naive schizophrenic patients: lack of influence of chronic perphenazine treatment.
Spivak B; Kosower N; Zipser Y; Shreiber-Schul N; Apter A; Tyano S; Weizman A
Clin Neuropharmacol; 1994 Feb; 17(1):83-8. PubMed ID: 8149362
[TBL] [Abstract][Full Text] [Related]
39. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
40. [Therapy control of perphenazine. 2. Clinical aspects].
Kjeldsen CS; Larsen NE; Kragh-Sørensen P; Andersen E; Brøsen K; Gerholt F; Glue P; Hørder M; Klitgaard NA; Krarup G
Ugeskr Laeger; 1991 Aug; 153(34):2339-43. PubMed ID: 1897043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
